News

News

Hear what the media is saying about Vistagen Therapeutics, and the products we are developing to exceed the current standard of care.

Media Coverage

Bio Report logo
The Bio Report: A Rapid Onset Nasal Spray to Treat Mental Health Conditions
Read
The Biotech Project
The Biotech Project: Featuring Shawn Singh
Read
BioSpace Logo
Combatting the Mental Health Crisis with an Acute Treatment Nasal Spray
Read

Press Releases

Preclinical data in "gold standard" MPTP non-human primate model of Parkinson's disease show significant reduction of levodopa-induced dyskinesia by AV-101, while maintaining antiparkinsonian activity of levodopa SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov.
PALISADE-2 Phase 3 trial with PH94B in social anxiety disorder restart preparations underway after independent interim analysis recommends study continue as planned Preliminary analysis of nearly 400 subjects in the final data set for the PALISADE Open Label Study demonstrates robust functional
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 4, 2022-- Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 3, 2022-- Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous